Get started
Author

Simon Joynson Cooper

Observed names: Simon Cooper, Simon J. Cooper
Institution: Hokkaido University
ORCID: 0000-0003-1465-5879
Observed ORCID: 0000-0003-1465-5879
OpenAlex ID: A5048817681
Photoexcitation of flavoenzymes enables a stereoselective radical cyclization
2019 · Kyle F. Biegasiewicz, Simon J. Cooper, et al. · Science · 445
PDF
Catalytic promiscuity enabled by photoredox catalysis in nicotinamide-dependent oxidoreductases
2018 · Kyle F. Biegasiewicz, Simon J. Cooper, et al. · Nature Chemistry · 184
Quaternary Charge-Transfer Complex Enables Photoenzymatic Intermolecular Hydroalkylation of Olefins
2020 · Claire G. Page, Simon J. Cooper, et al. · Journal of the American Chemical Society · 151
PDF
Codon-Precise, Synthetic, Antibody Fragment Libraries Built Using Automated Hexamer Codon Additions and Validated through Next Generation Sequencing
2015 · Laura Frigotto, Matthew Smith, et al. · Antibodies · 24
PDF
Photocatalytic Activation of Fluoroform for Radical Trifluoromethylation
2026 · Shun Zhou, Yan Song, et al. · Journal of the American Chemical Society · 1
Identifying viable synthetic routes from side channels in automated reaction-path searches
2026 · Yamato Ueno, Wataru Kanna, et al. · Communications Chemistry · 1
PDF
Intramolecular Hydride Transfer Racemization Coupled with Enzymatic Kinetic Resolution Enables Asymmetric Syntheses of Caged Compounds
2026 · Simon J. Cooper, Pingyu Jiang, et al. · The Journal of Organic Chemistry
Supplementary Figure Legend from Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers
2023 · Simon J. Cooper, Christina A. von Roemeling, et al.
PDF
Supplementary Figure 1 from Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers
2023 · Simon J. Cooper, Christina A. von Roemeling, et al.
Supplementary Figure 1 from Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers
2023 · Simon J. Cooper, Christina A. von Roemeling, et al.
PDF
Supplementary Figure 2 from Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers
2023 · Simon J. Cooper, Christina A. von Roemeling, et al.
PDF
Supplementary Figure 3 from Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers
2023 · Simon J. Cooper, Christina A. von Roemeling, et al.
Supplementary Figure 2 from Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers
2023 · Simon J. Cooper, Christina A. von Roemeling, et al.
Supplementary Figure 7 from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
2023 · Christina A. von Roemeling, Laura A. Marlow, et al.
PDF
Supplementary Figure 1 from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
2023 · Christina A. von Roemeling, Laura A. Marlow, et al.
PDF
Supplementary Figure Legend from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
2023 · Christina A. von Roemeling, Laura A. Marlow, et al.
Supplementary Figure 3 from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
2023 · Christina A. von Roemeling, Laura A. Marlow, et al.
PDF
Supplementary Data from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
2023 · Christina A. von Roemeling, Laura A. Marlow, et al.
Supplementary Figure 3 from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
2023 · Christina A. von Roemeling, Laura A. Marlow, et al.
Supplementary Figure 7 from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
2023 · Christina A. von Roemeling, Laura A. Marlow, et al.
Data from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
2023 · Christina A. von Roemeling, Laura A. Marlow, et al.
Supplementary Figure 4 from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
2023 · Christina A. von Roemeling, Laura A. Marlow, et al.
PDF
Supplementary Figure 2 from Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
2023 · Christina A. von Roemeling, Laura A. Marlow, et al.
Data from Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
2023 · Laura A. Marlow, Lisa A. Reynolds, et al.
Data Supplement from Neuronal Pentraxin 2 Supports Clear Cell Renal Cell Carcinoma by Activating the AMPA-Selective Glutamate Receptor-4
2023 · Christina A. von Roemeling, Derek C. Radisky, et al.
Works count: 45
Citation count: 806
H-index: 4
I10-index: 4
Year
Topic
Type